Office of the Vice-Principal (Research)

Office of the Vice-Principal (Research)
Office of the Vice-Principal (Research)

Canadian Cancer Trials Group (CCTG)

The Canadian Cancer Trials Group (CCTG) is a cooperative oncology group that designs and administers clinical trials in cancer therapy, supportive care and prevention across Canada. They support a collaborative network of researchers, physicians, scientists and statisticians internationally recognized for finding the treatments that give people with cancer longer, better quality lives.

Their mission is “to develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease.”

Created in 1980, the group has run trials resulting in major, life-saving breakthroughs in breast, colorectal, blood, lung, ovarian, brain and prostate cancer. CCTG is the only non-American partner of the US National Clinical Trials Network and internationally they have collaborated with sites and other cooperative groups around the world. These international partnerships are central to the success of their cancer clinical trials and crucial to the advancement of the cancer research agenda.

Canadian Cancer Trials Group
CCTG’s Central Operations and Statistics centre is located in the Cancer Research Institute at Queen’s University, with in house faculty researchers that include clinician scientists, researchers in community health and epidemiology, and biostatisticians. The CFI Major Science Initiatives funding supports the critical work at the Operations and Statistics centre where the central team contributes a wealth of knowledge and expertise in the design and analysis of clinical trials in Canada and around the world.

More recently, the CFI John R. Evans Leaders Fund (JELF) announced a funding award to allow the CCTG to acquire a state-of-the-art digital histology slide scanner. The scanner will enable CCTG to share digitized scans of slides of tumours with expert pathologists across Canada. This tool will accelerate more accurate diagnosis and classification of tumours, as well as, the detection and quantification of new biomarkers, which could lead to improved therapeutic strategies.

Distinguished Queen’s researchers, Dr. Lois Shepherd (Director of the CCTG Tumour Tissue Data Repository) and Dr. David LeBrun (Academic Director of the Queen’s Laboratory for Molecular Pathology) will be jointly overseeing the supervision for the scanner’s operation.

The Canadian Cancer Trials Group is supported by a core grant received from the Canadian Cancer
Society Research Institute and is one of the national programs of the Canadian Cancer Society (CCS)

Canadian Member Institutions

>85

Canadian Investigators

>2100

Clinical Trials

>500

Countries

>500

Publications

>1000

Funded by CFI –
 Major Science Initiatives 2017-2022 Competition: $8,675,000 (September 19, 2016)
 John R. Evans Leaders Fund: $197,065 (August 15, 2017)

www.ctg.queensu.ca